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Summary
Context Human growth hormone receptor (GHR) transcripts
have two isoforms, full-length (GHRﬂ) or exon 3 deleted (GHRd3).
An association of these isoforms has been found with small for ges-
tational age (SGA) infants but does not inﬂuence adult height. The
role of this polymorphism in the birth size spectrum in the general
population is unclear.
Objective To determine the association of maternal and infants
GHR exon 3 polymorphism with antenatal growth, birth size and
early postnatal growth in two large, normal white European birth
cohorts.
Study design Pregnant women from white European families
were recruited by the University College London Foetal Growth
Study (n = 774) and the Moore normal pregnancy cohort
(n = 274). GHR variants, wild-type (ﬂ) and deleted for exon 3 (d3)
were analysed using multiplex PCR.
Results There was a signiﬁcant underrepresentation of infants
wild-type ﬂ/ﬂ (36%) and overrepresentation of d3/d3 (14%) geno-
types in the SGA infants within the cohorts (v
2 =1 1 Æ2, P =0 Æ003,
df = 2). Fl/ﬂ was overrepresented in large for gestational age (LGA)
infants (v
2 =6 Æ1, P =0 Æ047, df = 2). There was a signiﬁcant asso-
ciation of infants GHR isoforms with placental weight (P <0 Æ001)
and birth weight standard deviation scores (P =0 Æ04) with the ﬂ/ﬂ
genotype associated with a larger placental and birth weight. In
multiple regression analysis, the GHR isoform type, maternal book-
ing weight and parity inﬂuenced placental weight (R
2 =0 Æ35;
P <0 Æ001, df = 7). The GHR isoform type was not related to ante-
natal anthropometric measurements or growth in infancy.
Conclusion These data suggest that the GHR isoforms are associ-
ated with placental and birth weight.
(Received 5 April 2011; returned for revision 25 April 2011; ﬁnally
revised 16 August 2011; accepted 16 August 2011)
Introduction
The growth hormone receptor (GHR) gene (MIM: *600946) is
located on chromosome 5 (5p13.1-p12) and consists of nine
coding exons.
1 In humans, GHR transcripts exist in two major
isoforms; retention (GHRﬂ) or exclusion of exon 3 (GHRd3).
GHR exon 3 skipping results from a homologous recombina-
tion of two retroviral sequences ﬂanking this exon that mimic
an alternative splicing event.
1 Historically exon 3 deletion was
ﬁrst reported as a potential pathological ﬁnding in two patients
with GH insensitivity.
2 Subsequent studies conﬁrmed GHR
exon 3 insertion/deletion as common polymorphism with these
isoforms speciﬁc to individuals
3 inherited as a Mendelian
trait.
4
During infancy and childhood pituitary, growth hormone
(hGH-N) and insulin-like growth 1 (IGF-1) inﬂuence growth
by virtue of hGH-N binding to the GHR. During pregnancy,
hGH-N expression in the mother is suppressed; and placental
growth hormone (hGH-V), a GH variant expressed by the pla-
centa, becomes the predominant GH in the mother.
5 hGH-V
inﬂuences placental and foetal growth by binding to the mater-
nal and placental GHR. Inherent variation in the GHR with
insertion/deletion of an exon could explain some of the vari-
ability seen in the antenatal and postnatal growth and response
to recombinant human GH (r-hGH) treatment in children with
growth disorders.
Dos Santos et al.
6 ﬁrst reported a positive inﬂuence of GHR exon
3 polymorphism on response to treatment with human GH in chil-
dren with idiopathic short stature (ISS) and those born small for
gestational age (SGA). However, no difference in the frequency of
this polymorphism was found in short children compared to con-
trol adults of normal height, suggesting that this polymorphism
was not primarily related to the aetiology of adult height.
6 This lack
of overall effect was postulated to be secondary to compensation by
endogenous pituitary GH secretion, masking any effect of the GHR
polymorphism on growth rate. Subsequently, a number of studies
of the polymorphism frequencies in various populations of chil-
dren with growth disorders have yielded inconsistent results
7
mainly due to small sample sizes.
8 A meta-analysis of all these
studies indicates that GHRd3 stimulates growth velocity by an
additional effect of 0Æ5 cm during the ﬁrst year of treatment with
r-hGH.
7
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morphism on antenatal and early postnatal growth with small sam-
ple sizes limiting interpretation.
9–11 We have evaluated the role of
GHR exon 3 isoform on antenatal growth, birth size, placental
weight and postnatal growth up to 3 years of age in two large
prospectively recruited white European cohorts.
Subjects and methods
Study cohort
Subjects for this study were recruited from two separate white
European cohorts, the University College London Hospital Fetal
Growth Study (UCL-FGS) (n = 1650) and the Moore cohort
(n = 310). Ethical approval was obtained from the University
College London Hospitals and Queen Charlotte Hospital for
Women and Hammersmith Hospital Ethics Committees. Written
informed consent was obtained from all the participants on
entrance into the study and then again for the participation of
the infant in the study after birth. Suitable DNA samples for this
study were available in 1048 infants, 774 from UCL-FGS and 274
from Moore cohort. Inclusion criteria in both cohorts were white
European families presenting for the ﬁrst prenatal visit before
20 weeks of pregnancy and ultrasound examination demonstrat-
ing a structurally normal single foetus. Pregnancies with antena-
tal complications and adverse foetal ﬁndings were excluded from
the study.
From UCL-FGS antenatal ultrasonographic growth data,
anthropometric measurement at birth and growth data until
3 years of age (n = 524) was used for the study. Data collection
was standardized, and all data were collected prospectively.
Antenatal growth measurements were performed by ultrasonog-
raphy by a single skilled physician with expertise in foetal medi-
cine. At birth, trimmed placental weight (stripped of blood
clots, umbilical cord and membranes) was recorded. Anthropo-
metric measures were undertaken at birth by a single observer.
Weight was measured using electronic self-calibrating scales
(Seca, Birmingham, UK), length by Infantometer (Child Growth
Foundation, London, UK) and head circumference using a ﬂexi-
ble metal tape. Three separate measurements were taken and the
mean recorded. All measurements at birth were corrected for
gestational age and sex by converting them into standard devia-
tion scores (SDS).
12 Similar postnatal anthropometric data were
collected at six monthly intervals by a single observer up to
3 years of age.
From Moore cohort anthropometric measurements at birth
were used. All families were of white European origin. Placental
sample was dissected and frozen at )80 C until use for foetal
DNA preparation. Blood samples were collected in EDTA tubes
from each parent for DNA extraction. Maternal weight, height,
age, parity, baby’s gender, birth weight, head circumference, pla-
cental weight, past and present medical history, mode and indica-
tion delivery for delivery, pregnancy complications, smoking, diet
and alcohol consumption, and partner’s medical history were col-
lected from the mother’s notes from all families participating in
the study. All measurements at birth were corrected for gestational
age and sex by converting them into standard deviation scores
(SDS).
12
Analysis of GH receptor isoforms
In the UCL-FGS cohort, genomic DNA was extracted from cord
blood (n = 449) and from placenta (n = 325) where suitable cord
blood sample was not available. In the Moore cohort, genomic
DNA samples were obtained from placental tissue (n = 274). Pla-
cental samples were dissected near the umbilical cord insertion
point, snapped frozen in liquid nitrogen and stored at )80 C until
use for foetal DNA preparation. DNA was extracted from the
maternal blood samples and stored for analyses of maternal geno-
type.
For genotyping of the GHR exon 3 locus, a simple multiplex PCR
assay was used as previously described (2). Ampliﬁcation products
were analysed by electrophoresis on a 1% agarose gel stained with
ethidium bromide. GHR ﬂ allele was detected as a single band cor-
responding to 935 bp and the GHR-d3 allele corresponding to
532 bp, respectively. All samples were coded, and the operator was
blinded to anthropometric data.
Statistics
All data were assessed for normal distribution by exploring the
data for skewness and kurtosis and the Shaprio–Wilks estimates.
Infants were deﬁned as SGA and large for gestational age (LGA)
if birth weights were below 10th centile or above 90th centile,
respectively, for gestational age. Postnatal catch-up or catch-
down growth was deﬁned as an increase or decrease in weight
SDS of 0Æ6 over the ﬁrst year of life.
13 In the UCL FGS cohort,
Student’s t-test was used to compare the GHR genotyped group
(n = 774) and total cohort (n = 1674) mean values to ensure
there was no selection bias in those samples used for genotype
analysis.
Chi-square tests were used to compare frequency distributions
of the GHR genotypes. One-way analysis of variance (anova), with
the Tukey’s honest signiﬁcant differences (HSD) post hoc test, was
used to determine differences between the mean anthropometric
measures in the GHR exon 3 genotypes. Multiple stepwise linear
regression was used to determine factors inﬂuencing placental
weight and birth weight SDS.
A sample size of 1048 was estimated to have a power of 90% to
calculate a 50 g difference in placental weight and 100 g difference
in birth weight at 5% level of signiﬁcance between SGA and LGA
groups.
Results
General
Both cohorts consisted of a total of 1048 singletons with equal
number of men and women. Maternal and infant cohort data
shown in Table 1 conﬁrm similarities of UCL-FGS and Moore
cohort. In the UCL-FGS, there was no difference in these data
between those who underwent GHR analysis (n = 774) and those
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had normal distribution and hence log transformation was not
required.
Infant GHR isoforms
The frequency distribution of the GHR exon 3 genotype was as fol-
lows: ﬂ/ﬂ 48%, ﬂ/d3 45% and d3/d3 7%. The genotype distribution
was in Hardy–Weinberg equilibrium. Parity and cigarette smoking
were distributed similarly across the GHR genotype (v
2 =0 Æ12,
P =0 Æ94, df = 4 and v
2 =0 Æ18, P =0 Æ91, df = 4 respectively).
In the UCL-FGS, GHR genotype was not associated with param-
eters of antenatal growth (Table 2). The effect of infant’s GHR
genotype on anthropometric measures on the entire cohort at birth
is shown in Table 2. GHR exon 3 genotype was signiﬁcantly associ-
ated with placental weight (one-way anova F =7 Æ557; P =0 Æ001,
df = 992) and birth weight SDS (one-way anova F =3 Æ3;
P =0 Æ037, df = 1047). In infant’s placenta, weight and birth weight
SDS was higher in the GHR ﬂ/ﬂ genotype group and lower in the
GHR d3/d3 genotype. GHR genotype was not signiﬁcantly associ-
ated with birth length SDS (one-way anova F =1 Æ6; P =0 Æ2,
df = 1020) or head circumference SDS (one-way anova
F =0 Æ865; P =0 Æ42, df = 1021).
There was a greater proportion of d3/d3 (14%) and lower pro-
portion of ﬂ/ﬂ (36%) in the SGA group at birth (v
2 =1 1 Æ2,
P =0 Æ003, df = 2). In the LGA category the ﬂ/ﬂ genotype was over-
represented (60%) and ﬂ/d3 and d3/d3 genotypes were underrepre-
sented (v
2 =6 Æ1, P =0 Æ047, df = 2) (Fig. 1).
In the UCL-FGS, no association of GHR genotype was found
with postnatal anthropometric data up to 3 years of age (data not
shown). GHR genotype was also not associated with catch-up
(v
2 =0 Æ28, P =0 Æ87, df = 2) or catch-down (v
2 =0 Æ58, P =0 Æ75,
df = 2) growth in the ﬁrst year of life.
In multiple regression analyses (adjusted R
2 35%), GHR geno-
type, booking weight, parity and gestational age of delivery were
associated with placental weight while maternal age and cigarette
smoking did not inﬂuence placental weight (Table 3). In multiple
regression analyses, birth weight SDS was not inﬂuenced by GHR
genotype (data not shown).
Table 1. Maternal and infant anthropometric and demographic data from
the UCL-FGS and the Moore cohort
UCL-FGS
n = 774
Moore cohort
n = 274
Maternal parameters
Maternal height (cm) 164Æ6( 6 Æ90) 165Æ8( 6 Æ25)
Maternal weight (kg) 63Æ9 (11Æ9) 66Æ8 (11Æ9)
Infant parameters
Gestation (weeks) 39Æ4( 1 Æ05) 39Æ1( 1 Æ00)
Placental weight (g) 699Æ2 (136Æ8) 708Æ8 (137Æ7)
Birth weight SDS 0Æ12 (0Æ98) 0Æ17 (0Æ93)
Birth length SDS )0Æ12 (0Æ75) –
Head circumference SDS )0Æ005 (0Æ003) )0Æ01 (0Æ004)
Data shown as mean with SD in parentheses.
UCL-FGS,University College London Hospital Fetal GrowthStudy; SDS,
standard deviationscores.
Table 2. Association of infant GHR exon 3 genotype with antenatal growth (n = 774), placental weight and anthropometric measurements at birth
(n = 1048)
Anthropometric measurements
GHR exon 3 genotype
GHR ﬂ/ﬂ (48%) GHR ﬂ/d3 (45%) GHR d3/d3 (7%) df P value
First trimester (12–14 weeks of gestational age)
Femur length (cm) 1Æ9( 0 Æ6) 1Æ8( 0 Æ55) 1Æ8( 0 Æ65) 754 (2) 0Æ55
Abdominal circumference (cm) 14Æ3( 1 Æ4) 13Æ7( 2 Æ3) 13Æ1( 2 Æ0) 759 (2) 0Æ66
Bi parietal diameter (cm) 3Æ0( 0 Æ7) 2Æ9( 0 Æ7) 2Æ9( 0 Æ6) 760 (2) 0Æ51
Second trimester (18–20 weeks of gestational age)
Femur length (cm) 3Æ3( 0 Æ3) 3Æ3( 0 Æ3) 3Æ2( 0 Æ2) 750 (2) 0Æ77
Abdominal circumference (cm) 15Æ7( 1 Æ3) 15Æ7( 1 Æ3) 15Æ6( 1 Æ0) 759 (2) 0Æ83
Bi parietal diameter (cm) 4Æ95 (0Æ32) 4Æ95 (0Æ42) 4Æ90 (0Æ22) 760 (2) 0Æ61
Third trimester (30–34 weeks of gestational age)
Femur length (cm) 6Æ2( 0 Æ3) 6Æ2( 0 Æ3) 6Æ1( 0 Æ4) 700 (2) 0Æ46
Abdominal circumference (cm) 28Æ7( 1 Æ8) 28Æ6( 1 Æ7) 28Æ4( 2 Æ1) 700 (2) 0Æ70
Bi parietal diameter (cm) 8Æ5( 0 Æ43) 8Æ4( 0 Æ38) 8Æ3( 0 Æ50) 615 (2) 0Æ08
Birth
Placental weight (g) 697 (142) 665 (131) 656 (136) 990 (2) 0Æ001*
Birth weight SDS 0Æ22 (1Æ0) 0Æ14 (0Æ95) 0Æ05 (0Æ90) 1045 (2) 0Æ037*
Birth length SDS (UCL-FGS,n = 774) )0Æ04 (1Æ17) )0Æ18 (1Æ14) )0Æ21 (1Æ08) 1018 (2) 0Æ2
Head circumference SDS 0Æ05 (1Æ13) )0Æ05 (1Æ09) )0Æ04 (0Æ95) 1019 (2) 0Æ42
Data shown as mean with SD in parentheses, P value calculated by one-way analysis of variance (anova).
SDS, standarddeviation scores; UCL-FGS, UniversityCollege London Hospital Fetal GrowthStudy; df, degree of freedom within-group with between-group
combined in parentheses.
*Signiﬁcant P value. Antenatal growth parameters analysed in UCL-FGSn = 774. Placental weight and postnatal growth analysed in UCL-FGS and Moore
cohort, n = 1048.
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Maternal GHR genotype did not demonstrate any signiﬁcant asso-
ciation with placental weight or any anthropometric measures at
birth (Table 4).
Discussion
In a cohort of white European pregnant women andtheir offspring,
we found a signiﬁcant positive association between GHR exon 3
genotype and placental and birth weight. This genotype appears to
inﬂuence intrauterine growth in late gestation as our study demon-
strated no clear effect on ultrasonographic measures of antenatal
growth up to the third trimester of pregnancy (30–32 week scan).
Further, the effect does not seem to be maintained into postnatal
life as no long-term effect on size could be determined nor on the
catch-up and catch-down growth process.
Adequate placentation and placental growth are essential for foe-
tal growth. There is a strong correlation between placental weight
and foetal growth with most low birth infants having a small pla-
centa.
14,15 This implies that placental growth is linked to foetal
growth. The placenta expresses GHR, which can bind the increas-
ing concentrations of placental growth hormone (hGH-V)
encoded by chorionic somatomammotropin hormone 1 (CSH1),
(MIM: *150200) during pregnancy. hGH-V is secreted by syncytio-
trophoblasts and its concentration progressively rises in maternal
plasma from 10–12 weeks of gestation to term.
16 hGH-V is also
expressed in invasive extravillous trophoblasts suggesting that the
physiological role of hGH-V, in addition to endocrine effects in the
mother, might also include a direct inﬂuence on placental develop-
ment via an autocrine or paracrine mechanism.
17 hGH-V is
expressed in the placenta
18 and could potentially inﬂuence auto-
crine or paracrine effects of placental or foetal GH on placental
growth.
10 Circumstantial evidence for this comes from the observa-
tion that deletion of the PGH gene in the foetus is associated with
marked foetal growth restriction and a small placenta
19 and that
the placental weight of GHRﬂ/ﬂ group in our study was heavier
than that of the GHRd3/d3 group.
Our data would suggest that the size of the effect on birth weight
is less than that upon the placenta but given the interaction of pla-
cental weight and birth size it is not easy to dissect this further. In
the multiple linear regression model, placental weight is inﬂuenced
by GHR genotype, while birth weight SDS is not suggesting that
GHR genotype effect on birth weight could be mediated through
placental weight.
Jensen et al.
10 have demonstrated an inﬂuence of GHR exon 3
deleted genotype on foetal growth velocity in SGA infants and
increased postnatal growth in both SGA and appropriate for
gestational age (AGA) infants. Sorensen et al.
11 have shown
decrease in birth weight and birth length in GHR d3/d3 genotype
similar to our study. Unlike other studies, we could not demon-
strate any effect on prenatal weight up to 32 weeks of gestational
age and postnatal growth. This probably reﬂects the fact that our
cohort represents a continuum across the birth size spectrum in the
general population and does not represent polarized size class
groups. In addition, the larger sample size in our study reduces the
likelihood of false-positive ﬁndings.
Table 3. Multiple stepwise linear regression analyses of factors inﬂuencing
placental weight
Covariate Coefﬁcient t-ratio P value
GHR genotype )0Æ13 )3Æ482 0Æ001
Booking weight 0Æ12 3Æ15 0Æ002
Gestational age at delivery 0Æ28 7Æ55 0Æ0001
Parity 0Æ14 3Æ73 0Æ0001
Degree of freedom for regression = 7, residuals = 664.
Table 4. Association of maternal GHR exon 3
genotype with placental weight and infant
anthropometric measureat birth
GHR exon 3 genotype
GHR ﬂ/ﬂ (49%) GHR ﬂ/d3 (40%) GHR d3/d3 (11%) P value
Placental weight (g) 691 (134) 685 (130) 705 (137) 0Æ2
Birth weight SDS 0Æ2( 1 Æ0) 0Æ7( 0 Æ85) 0Æ36 (0Æ90) 0Æ09
Birth length SDS (UCL-FGS) )0Æ03 (0Æ27) )0Æ18 (1Æ04) )0Æ21 (1Æ08) 0Æ12
Head circumference SDS )0Æ05 (0Æ13) )0Æ15 (1Æ09) 0Æ12 (0Æ85) 0Æ42
Data shown as mean with SD in parentheses, P value calculated by one-way analysis of variance
(anova).
SDS, standarddeviation scores; UCL-FGS, UniversityCollege London Hospital Fetal GrowthStudy.
Fig. 1 Frequency of GHR exon 3 genotypes based on birth weight centile.
Chi-square P value; <10th centile – 0Æ003, >90th centile – 0Æ047, df = 2.
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not found any inﬂuence of GHR locus on height or metabolic
parameters.
20 This could simply mean that GHR variation does not
signiﬁcantly inﬂuence growth or the SNP that tags GHR exon 3 in
the GWAS does not recapitulate all the genomic variability at the
locus, including the d3, other copy number variations, or rare vari-
ants.
21
In conclusion, we found that the GHR exon 3 polymorphism
genotype is associated with placental weight and birth weight with
carriers of GHRﬂ/ﬂ allele having a heavier placenta and higher birth
weight. Placental weight could be potentially inﬂuenced by an
autocrine/paracrine action of hGH-V or other products of the
chorio-somatomammotropic gene on the GHR polymorphism
present in the placenta.
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